Switching to a once-daily bictegravir/lenacapavir (BIC/LEN) single-tablet regimen is generally well tolerated through 48 ...

South Africa has 8 million people living with HIV, and the government has introduced lenacapavir, a new HIV prevention drug.

The new RFD4-Proteina unified generative model for protein design—created by the Institute for Protein Design (IPD) in ...

All 46 people with HIV who started long-acting lenacapavir and cabotegravir at a University of California, San Francisco, ...

South Africa’s rollout of lenacapavir, a six-monthly HIV prevention injection, requires nurses to learn, adapt and find ways ...

Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Astute Optics – US’s Substack. In ...

More than 41 million people are living with HIV worldwide, and approximately 570,000 died from AIDS-related illnesses in 2025 ...

A medicine injected just twice a year could transform the fight against HIV. In a 2024 clinical trial involving more than 2,000 young women in South Africa and Uganda, no participants who received ...

With permission from his family and partners at Haven Health, we are publishing his story posthumously in recognition of his ...

Manchester scientists test AI-designed enzymes for key step in lenacapavir synthesis, showing how protein design could ...

Among the 100 recipients, median time from prescription to first injection was 12 days (interquartile range [IQR], 6-23). In ...

When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each ...